Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
|Brain Tumor||Procedure: Magnetic Resonance Imaging Procedure: Diffusion Tensor Imaging Procedure: Magnetic Resonance Spectroscopic Imaging Procedure: Dynamic Contract-Enhanced magnetic resonance imaging Procedure: Diffusion-weighted magnetic resonance imaging|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy|
- Early brain tumor response
- Early therapeutic-induced changes in normal surrounding brain
|Study Start Date:||July 2009|
|Study Completion Date:||December 2012|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
Procedure: Magnetic Resonance Imaging
Other Name: MRI,NMR imaging, NMRI, nuclear magnetic resonance imagingProcedure: Diffusion Tensor Imaging Procedure: Magnetic Resonance Spectroscopic Imaging
Other Name: 1H-nuclear magnetic resonance spectroscopic imaging, Proton Magnetic Resonance Spectroscopic ImagingProcedure: Dynamic Contract-Enhanced magnetic resonance imaging
Other Name: DCE-MRIProcedure: Diffusion-weighted magnetic resonance imaging
Other Name: diffusion-weighted MRI
I. To develop a multimodality statistical model to act as a surrogate marker scheme of early changes in high grade glioma patients undergoing radiation therapy, using conventional MRI, MR diffusion tensor imaging, perfusion, permeability, and spectroscopic imaging while incorporating the radiation dose calculations delivered locally and the results of a clinical questionnaire into the model.
II. To assess treatment response to tumor and normal tissue changes. OUTLINE: Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6, and then 4-6 weeks after completion of radiation therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01018329
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|